Business Description
Foghorn Therapeutics is a US-based drug development company focused on treating cancers driven by specific genetic defects in the body's chromatin regulatory system. Using its proprietary Gene Traffic Control platform, the company identifies and pursues new treatment targets that other approaches may overlook. Its pipeline includes therapies for several cancer types, such as lung, endometrial, ovarian, bladder, and blood cancers, and it is advancing one of its key drugs in partnership with Eli Lilly and Company. Founded in 2015 and based in Watertown, Massachusetts, Foghorn is working to bring more precise cancer treatments to patients with limited options.
